Stockscreener 앱 받기
297.73
2.19%
-7.3273
전일 마감가:
$305.06
열려 있는:
$302.43
하루 거래량:
485.71K
Relative Volume:
0.46
시가총액:
$39.76B
수익:
$4.29B
순이익/손실:
$577.22M
주가수익비율:
70.74
EPS:
4.2086
순현금흐름:
$641.34M
1주 성능:
+0.31%
1개월 성능:
-0.93%
6개월 성능:
-33.87%
1년 성능:
+1.87%
1일 변동 폭
$297.73
$305.68
1주일 범위
$291.84
$305.98
52주 변동 폭
$284.28
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY vs VRTX, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
297.77 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
VRTX
Vertex Pharmaceuticals Inc
|
445.81 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.74 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.68 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
155.37 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-07 | 재개 | Oppenheimer | Outperform |
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Adding Scientific Depth Amid RNAi Pipeline Scrutiny - simplywall.st
ALNY Stock Price, Quote & Chart | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Alnylam Pharmaceuticals, Inc. 8-K SEC Filing Summary – Corporate Details and Exchange Listing (May 20, 2026) - Minichart
Alnylam (NASDAQ: ALNY) expands board and details 2026 shareholder meeting votes - Stock Titan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $445 - Moomoo
Ionis, Alnylam, BioMarin up as Citi starts at buy on catalyst and growth outlook - MSN
ALNY Technical Analysis | Trend, Signals & Chart Patterns | ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - ChartMill
Citi Initiates Alnylam (ALNY) With Buy Rating - Insider Monkey
Alnylam Pharmaceuticals Q3 2025 Earnings Preview - MSN
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A 49.88% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Assessing Alnylam Pharmaceuticals (ALNY) Valuation After Mixed Share Performance And Strong AMVUTTRA Uptake - simplywall.st
Director at Alnylam (NASDAQ: ALNY) granted RSUs and stock options - Stock Titan
Alnylam (NASDAQ: ALNY) awards RSUs and options to board director - Stock Titan
Director at Alnylam (NASDAQ: ALNY) receives RSUs and options - Stock Titan
Alnylam (ALNY) director gets new RSUs, options and reports trust holdings - Stock Titan
Director Peter Kellogg granted RSUs and stock options at Alnylam (NASDAQ: ALNY) - Stock Titan
ALNY (ALNY) director granted 671 RSUs and 1,441 options at $298.48 - Stock Titan
Alnylam (ALNY) director Olivier Brandicourt receives new RSU and option grants - Stock Titan
ALNY (ALNY) director Dennis Ausiello granted RSUs and stock options awards - Stock Titan
Alnylam (ALNY) director granted RSUs and stock options in new equity awards - Stock Titan
Discipline and Rules-Based Execution in ALNY Response - Stock Traders Daily
Alnylam Pharmaceuticals (ALNY) 10K Form and Latest SEC Filings 2026 - MarketBeat
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure By Investing.com - Investing.com South Africa
Alnylam Pharmaceuticals’ SWOT analysis: stock faces margin pressure - Investing.com
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth - Eastern Progress
Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
ALNY Technical Analysis & Stock Price Forecast - Intellectia AI
ALNY Initiated Coverage by Citigroup -- Price Target Set at $380 - GuruFocus
Citi Initiates Coverage on Biotech Stocks: Ionis (IONS), Alnylam (ALNY), BioMarin (BMRN) - GuruFocus
Ionis, Alnylam, BioMarin are new Buys at Citi (ALNY:NASDAQ) - Seeking Alpha
Alnylam Issues 2025 Corporate Responsibility Report - BioSpace
Alnylam commits $2M to frontline care navigators in Boston - Stock Titan
How HELIOS-B Phase 3 Vutrisiran Data and Real-World Evidence Expansion Will Impact Alnylam (ALNY) Investors - simplywall.st
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Proactive financial news
Daily Brief Health Care: Dermavon Holdings, Alebund Pharmaceuticals Jiangsu, Alnylam Pharmaceuticals, Artrya , Bavarian Nordic A/S, Cardinal Health, Dexcom Inc, American Shared Hospital Servi, Eli Lilly & Co, Abeona Therapeutics and more - Smartkarma
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment - GlobeNewswire Inc.
How Investors Are Reacting To Alnylam Pharmaceuticals (ALNY) New HELIOS-B Vutrisiran Data And Real-World Study - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by iA Global Asset Management Inc. - MarketBeat
Alnylam’s Vutrisiran Data And Real-World Study Contrast With Depressed Valuation - Yahoo Finance
Alnylam Pharmaceuticals, Inc. $ALNY Position Reduced by DNB Asset Management AS - MarketBeat
Is the options market predicting a spike in Alnylam Pharmaceuticals stock? - MSN
ALNY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by ANTIPODES PARTNERS Ltd - MarketBeat
Alnylam Pharmaceuticals Adjusts Valuation Grade Amid Strong Financial Performance Indicators - Markets Mojo
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As HELIOS B Data And TTR Guidance Reassure Investors - simplywall.st
Alnylam teams up with Viz.ai and American Heart Association to advance ATTR-CM care - MSN
Alnylam reiterates 2026 TTR sales guidance of $4.4B-$4.7B while expanding TRITON-CM enrollment to about 1,750 - MSN
Alnylam (NASDAQ: ALNY) director exercises 11,250 stock options at $70.20 - Stock Titan
Is Alnylam (ALNY) One of the Best Aggressive Growth Stocks to Buy? - Insider Monkey
Capital World Investors holds 10.9M Alnylam shares (NASDAQ: ALNY) - Stock Titan
Capital Research holds 9.47M shares of Alnylam (NASDAQ: ALNY) in 13G/A - Stock Titan
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.07%
2.80%
자본화:
|
볼륨(24시간):